ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
about
Key Targets for Multi-Target Ligands Designed to Combat NeurodegenerationDual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.Changing paradigm from one target one ligand towards multi target directed ligand design for key drug targets of Alzheimer disease: An important role of Insilco methods in multi target directed ligands design.Evidence for a Cyanine Link Between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism.
P2860
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@en
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@nl
type
label
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@en
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@nl
prefLabel
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@en
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
@nl
P2093
P2860
P50
P356
P1476
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
@en
P2093
Gerard Esteban
José Marco-Contelles
Lhassane Ismaili
Ricard Martínez-Murillo
Rona R Ramsay
P2860
P356
10.3389/FNINS.2016.00294
P577
2016-06-28T00:00:00Z